|
| | Issue Date | Title | Contributor(s) | Type | Cat. |
| 1 | 2022 | Cognitive improvements accompanied with WPAI improvements in OCR-treated patients with RRMS: 96-week CASTING data | Vermersch, P.; Comi, G.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Wiendl, H.; Buffels, R.; Kuenzel, T.; Benedict, R. | Journal Contribution | M |
| 2 | 2022 | Efficacy and safety of ocrelizumab is maintained in patients with RRMS with suboptimal response to prior disease-modifying therapies: 4-year NEDA data from CASTING-LIBERTO | Oreja-Guevara, C.; Benedict, R. H.; Comi, G.; Cutter, G.; Kister, I.; Siva, A.; Wiendl, H.; VAN WIJMEERSCH, Bart; Wuerfel, J.; El Azzouzi, B.; Buffels, R.; Dirks, P.; Kuenzel, T.; Vermersch, P. | Journal Contribution | M |
| 3 | 2022 | Cognitive improvements in ocrelizumab-treated patients with relapsing-remitting multiple sclerosis: 96-week CASTING study data | Benedict, R. H.; Comi, G.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Wiendl, H.; Buffels, R.; Kuenzel, T.; Vermersch, P. | Journal Contribution | M |
| 4 | 2022 | Employment and cognitive improvements in ocrelizumab-treated patients with relapsing-remitting multiple sclerosis: 96-week CASTING study data | Wiendl, H.; Benedict, R. H.; Comi, G.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Buffels, R.; Kuenzel, T.; Vermersch, P. | Journal Contribution | M |
| 5 | 2022 | Employment and Cognitive Improvements in Ocrelizumab-Treated Patients with Relapsing-Remitting Multiple Sclerosis: 96-Week CASTING Study Data | Wiendl, H.; Benedict, R.H.B.; Comi, G.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Buffels, R.; Kuenzel, T.; Vermersch, P. | Conference Material | C2 |
| 6 | 2021 | Efficacy and safety of ocrelizumab in patients with RRMS with suboptimal response to prior disease-modifying therapies: 3-year data from CASTING and LIBERTO 1-year interim results | VAN WIJMEERSCH, Bart; Comi, G.; Oreja-Guevara, C.; Wiendl, H.; Wuerfel, J.; Buffels, R.; Dirks, P.; Kuenzel, T.; Kadner, K.; Vermersch, P. | Journal Contribution | M |
| 7 | 2020 | Efficacy/safety Of Ocrelizumab In Relapsing-remitting MS Patients With Suboptimal Response To Prior Disease-modifying Therapies (1-yr Interim Results) | Vermersch, P.; Eralinna, J.; Nicholas, R.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Wiendl, H.; Buffels, R.; Wei, W.; Comi, G. | Journal Contribution | M |
| 8 | 2020 | Ocrelizumab phase iiib efficacy from casting: 2-year neda (mri re-baselined) subgroup rates in rrms patients with a suboptimal response to prior dmts | Wiendl, H.; Comi, G.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Wuerfel, J.; Buffels, R.; Kadner, K.; Kuenzel, T.; Vermersch, P. | Journal Contribution | M |
| 9 | 2019 | Use of other disease-modifying therapies after or between alemtuzumab treatments: pooled results from the CAMMS223, and CARE-MS I and II studies over 8 years | Vermersch, P.; Baker, M.; Bass, A. D.; Berkovich, R.; Comi, G.; Eichau, S.; Graves, D.; Hunter, S. F.; Ionete, C.; Limmroth, V.; Meuth, S. G.; Naismith, R. T.; Sharrack, B.; Subei, A.; Daizadeh, N.; Choudhry, Z.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 10 | 2019 | Alemtuzumab improves outcomes in RRMS patients who switched from SC IFNB-1a: 6-year follow-up of CARE-MS I Patients (TOPAZ Study) | Montalban, X.; Barone, D.; Broadley, S.; Dive, D.; Hupperts, R. M.; Lycke, J.; Massacesi, L.; Naismith, R. T.; Nakamura, K.; Pandey, K.; Schippling, S.; Vermersch, P.; Wiendl, H.; Chung, L.; Daizadeh, N.; Afsar, S.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 11 | 2019 | Ocrelizumab treatment satisfaction in patients with suboptimal response to previous disease-modifying therapies | VAN WIJMEERSCH, Bart; Buffels, R.; Clinch, S.; Kuhelj, R.; Wei, W.; Vermersch, P. | Journal Contribution | M |
| 12 | 2019 | Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with a suboptimal response to previous disease-modifying therapies (1-year interim results) | Vermersch, P.; Eralinna, J. -P.; Nicholas, R.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Wiendl, H.; Buffels, R.; Kuhelj, R.; Wei, W.; Comi, G. | Journal Contribution | M |
| 13 | 2018 | Alemtuzumab provides durable clinical efficacy in patients with active rrms in the absence of continuous treatment: 7-Year follow-up of CARE-MS I (TOPAZ Study) | VAN WIJMEERSCH, Bart; Vermersch, P.; Boyko, A.; de Seze, J.; Hartung, H. -P.; Havrdova, E. Kubala; Inshasi, J. Said; McCombe, P.; Montalban, X.; Pozzili, C.; Melanson, M.; Daizadeh, N.; Rodriguez, C.; Selmaj, K. | Journal Contribution | M |
| 14 | 2018 | Long-term Improvement in Clinical Outcomes in Alemtuzumab-Treated RRMS Patients Who Relapsed Between Courses 1 and 2 (CARE-MS I) | Broadley, S.; Wiendl, Heinz; Fernandez, O.; Freedman, M. S.; Izquierdo, G.; Lycke, J.; Pozzilli, C.; Sharrack, B.; Singer, B. A.; Steingo, B.; Vermersch, P.; Wray, S.; VAN WIJMEERSCH, Bart; Ziemssen, T.; Margolin, D. H.; Thangavelu, K.; Boster, A. | Journal Contribution | M |
| 15 | 2018 | Alemtuzumab outcomes over 6 years in RRMS patients who switched from SC IFNB-1a: follow-up of CARE-MS I patients (TOPAZ study) | VAN WIJMEERSCH, Bart; Barone, D.; Broadley, S.; Dive, D.; Hupperts, R. M. M.; Lycke, J.; Massacesi, L.; Montalban, X.; Naismith, R. T.; Pandey, K.; Schippling, S.; Vermersch, P.; Chung, L.; Daizadeh, N.; Rodriguez, C. E.; Nakamura, K.; Wiendl, H. | Journal Contribution | M |
| 16 | 2016 | Design of two phase III open-label trials evaluating ocrelizumab in patients with relapsing-remitting multiple sclerosis and suboptimal response to disease-modifying treatment | Bermel, R.; Comi, G.; Eralinna, J. -P.; Leist, T. P.; Nicholas, R.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Wiendl, H.; Bernasconi, C.; Buffels, R.; Csoboth, C.; Han, J.; Musch, B.; Vermersch, P. | Journal Contribution | M |
| 17 | 2016 | Durable improvement in clinical outcomes in treatmentnaive patients with relapsing-remitting multiple sclerosis who switched from SC IFNB-1a to alemtuzumab (care-MS I extension study 4-year follow-up) | Oreja-Guevara, C.; Alroughani, R.; Brassat, D.; Boyko, A. N.; McCombe, P.; Steingo, B.; VAN WIJMEERSCH, Bart; Margolin, D. H.; Thangavelu, K.; Rodriguez, C. E.; Vermersch, P. | Journal Contribution | M |
| 18 | 2016 | Alemtuzumab provides durable improvements in clinical outcomes in treatment-naive patients with active relapsing-remitting multiple sclerosis over 6 years in the absence of continuous treatment (CARE-MS I). | Coles, A. J.; Boyko, A. N.; Cohen, J. A.; De Seze, J.; Fox, E. J.; Havrdova, E.; Hartung, H. -P.; Inshasi, J. S.; McCombe, P.; Selmaj, K. W.; Vermersch, P.; VAN WIJMEERSCH, Bart; Margolin, D. H.; Thangavelu, K.; Rodriguez, C. E.; Montalban, X. | Journal Contribution | M |
| 19 | 2014 | Significant and meaningful improvement in treatment satisfaction with teriflunomide versus subcutaneous ifnb-1A in patients with relapsing ms results from tenere | Maurer, M.; VAN WIJMEERSCH, Bart; de Seze, J.; Meca-Lallana, J.; Bozzi, S.; Vermersch, P. | Journal Contribution | M |
Loading...
5
0
5
0
false